Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

HanAll's Partner HBM Announces Positive Topline Results from Phase 2 of Batoclimab in MG


Related Data

HanAll Biopharma (KRX: 009420.KS) today announced that its partner for HL161 (batoclimab) & HL036 (tanfanercept)​, Harbour BioMed, reported positive topline results from Phase 2 of batoclimab in MG.


- HBM press release link: